A business success story has both UCLA and a team of enterprising UCLA scientists envisioning a brighter future for cancer research and patient care.
In 1996, a unique collaboration of leading UCLA scientists led by Dr. Arie Belldegrun founded the biotechnology company Agensys Inc. and the company now stands to reap $537 million through an acquisition by Astellas Pharma Inc., making it one of the largest Los Angeles-based private biotech firms poised to tackle therapeutic, fully human monoclonal antibody oncology research and drug development.
According to Astellas, the acquisition will enable Agensys to become the cornerstone of the companys biologics efforts and will allow the Agensys team to accelerate its discovery and commercial efforts while working to achieve the vision of building a global leader in biologics and oncology.
Agensys, originally known as UroGenesys, was created with $8 million in seed money from private donors and angel investors, many of whom were grateful patients of the UCLA physicians who had helped spur the development of novel gene-based therapies for prostate cancer, the most common cancer in men.
As clinicians and scientists, we wanted to build on the discoveries made in our individual labs to help move cancer research forward from the bench to the bedside, said Belldegrun, founding chairman of Agensys, professor and chief of urologic oncology in the department of urology at the David Geffen School of Medicine at UCLA, and a researcher with UCLAs Jonsson Cancer Center.
The UCLA scientists worked with former president and chief executive officer of Teledyne Technologies Dr. Donald B. Rice, who became CEO of Agensys. They were joined in 1999 by Dr. Aya Jakobovits, who helped develop monoclonal antibody technology at the company. Today, Agensys specializes in the discovery of proprietary targets for a variety of cancer indications and in antibody product development, manufacturing
'/>"/>
| Contact: Rachel Champeau rchampeau@mednet.ucla.edu 310-794-0777 University of California - Los Angeles Source:Eurekalert |
Related biology news :
1. How the public perceives biotech
2. Monsanto expands sponsorship for Peking-Yale Joint Agrobiotechnology Center
3. UK scientists working to help cut ID theft
4. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
5. Comet probes reveal evidence of origin of life, scientists claim
6. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
7. Male elephants get photo IDs from scientists
8. Scientists retrace evolution with first atomic structure of an ancient protein
9. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
10. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
11. Clemson scientists shed light on molecules in living cells
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |